Core outcomes and definitions for pediatric fever and neutropenia research: A consensus statement from an international panel

Pediatric Blood and Cancer

Volumn 62, Issue 3, 2015, Pages 483-489

  Haeusler, Gabrielle M ^a,b,c   Phillips, Robert S ^d,e   Lehrnbecher, Thomas ^f   Thursky, Karin A ^a,g   Sung, Lillian ^h   Ammann, Roland A ⁱ  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b SOUTHERN HEALTH   (Australia)

^c Paediatric Integrated Cancer Service   (Australia)

^d UNIVERSITY OF YORK   (United Kingdom)

^e Leeds Children's Hospital   (United Kingdom)

^f GOETHE UNIVERSITY   (Germany)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

ⁱ UNIVERSITY OF BERN   (Switzerland)

Author keywords

Child; Consensus; Definitions; Fever; Neutropenia; Outcomes

Indexed keywords

ARTICLE; BODY TEMPERATURE; CHILDHOOD CANCER; CHILDHOOD DISEASE; CLINICAL RESEARCH; CONSENSUS; DELPHI STUDY; FEBRILE NEUTROPENIA; FEVER; HUMAN; MEDICAL RESEARCH; NEUTROPENIA; NEUTROPHIL COUNT; NURSE; OUTCOME ASSESSMENT; PATIENT; PHARMACIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; ADOLESCENT; CHILD; CLASSIFICATION; CLINICAL TRIAL; FEMALE; INFANT; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; QUESTIONNAIRE;

ADOLESCENT; BIOMEDICAL RESEARCH; CHILD; CHILD, PRESCHOOL; CONSENSUS; FEMALE; FEVER; HUMANS; INFANT; MALE; NEUTROPENIA; QUESTIONNAIRES;

EID: 84921369537     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25335     Document Type: Article

References (49)

1. Sinha I, Jones L, Smyth RL, Williamson PR. A systematic review of studies that aim to determine which outcomes to measure in clinical trials in children. PLoS Med 2008; 5:e96.
2. Haeusler GM, Phillips RS, Lehrnbecher T, Sung L, Ammann RA. The reporting of outcomes in studies of fever and neutropenia in children with cancer: Time for consensus. Pediatr Blood Cancer 2013; 60:1563-1564.
3. Kirkham JJ, Gargon E, Clarke M, Williamson PR. Can a core outcome set improve the quality of systematic reviews?-A survey of the Co-ordinating Editors of Cochrane Review Groups. Trials 2013; 14:21.
4. Phillips B, Wade R, Stewart LA, Sutton AJ. Systematic review and meta-analysis of the discriminatory performance of risk prediction rules in febrile neutropaenic episodes in children and young people. Eur J Cancer 2010; 46:2950-2964.
5. Phillips RS, Lehrnbecher T, Alexander S, Sung L. Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with febrile neutropenia. PLoS ONE 2012; 7:e38300.
6. Phillips RS, Wade R, Lehrnbecher T, Stewart LA, Sutton AJ. Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Medicine 2012; 10:6.
7. Haeusler GM, Carlesse F, Phillips RS. An updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment of fever during neutropenia in children with cancer. Pediatr Infect Dis J 2013; 32:e390-e396.
8. Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M. A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies. Brit J Haem 1997; 99:580-588.
9. Gargon E, Gurung B, Medley N, Altman DG, Blazeby JM, Clarke M, Williamson PR. Choosing important health outcomes for comparative effectiveness research: A systematic review. PLoS ONE 2014; 9:e99111.
10. Kirkham J, Boers M, Tugwell P, Clarke M, Williamson P. Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. Trials 2013; 14:324.
11. Core Outcome Measures in Effectiveness Trials (COMET). http://www.comet-initiative.org/. Accessed September 11, 2014.
12. Sinha IP, Smyth RL, Williamson PR. Using the Delphi technique to determine which outcomes to measure in clinical trials: Recommendations for the future based on a systematic review of existing studies. PLoS Med 2011; 8:e1000393.
13. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs 2000; 32:1008-1015.
14. Lehrnbecher T, Phillips R, Alexander S, Alvaro F, Carlesse F, Fisher B, Hakim H, Santolaya M, Castagnola E, Davis BL, Dupuis LL, Gibson F, Groll AH, Gaur A, Gupta A, Kebudi R, Petrilli S, Steinbach WJ, Villarroel M, Zaoutis T, Sung L. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol 2012; 30:4427-4438.
15. Philli RS, Sutton AJ, Riley R, Chisholm JC, Picton S, Stewart LA. Predicting infectious complications in neutropenic children and young people with cancer (IPD Protocol). Systematic Reviews 2012;1.
16. Paul A, Harris RT, Thielke R, Payne J, Gonzalez J, Conde JG. Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42:377-381.
17. Gibson F, Chisholm J, Blandford E, Donachie P, Hartley J, Lane S, Selwood K, Skinner R, Phillips R, Group CSC. Developing a national 'low risk' febrile neutropenia framework for use in children and young people's cancer care. Support Care Cancer 2013; 21:1241-1251.
18. Hirsch H, Boeckh M, Einsele H, Martino R, Ward K, Ljungman P. Fourth European Conference on Infections in Leukaemia. Community acquired respiratory virus infections other than Influenza and Adenovirus. http://www.ebmt.org/Contents/Resources/Library/ECIL/Documents/Community-acquiredrespiratoryvirus(CARV)infectionsotherthanInfluenzaandAdenovirus.pdf. Published February 6, 2012, Accessed September 12, 2014.
19. Engelhard D, Bilal M, de la Camara R, Ljungman P. Fourth European Conference on Infections in Leukaemia.Influenza. http://www.ebmt.org/Contents/Resources/Library/ECIL/Documents/Influenza ECIL 4 final.pdf. Published January 27, 2012, Accessed September 12, 2014.
20. Matthes-Martin S, Feuchtinger T, Shaw P, Engelhard D, Ljungman P. Fourth European Conference on infections in Leukaemia.Management of adenovirus (ADV) infections. http://www.ebmt.org/Contents/Resources/Library/ECIL/Documents/ECIL4 2011 Adenovirus.pdf. Published January 27, 2012, Accessed September 12, 2014.
21. Ljungman P, de la Camara R, Einsele H, Engelhard D, Reusser P, Styczynski J, Ward K. Fourth European Conference on Infections in Leukaemia. Recommendations for CMV and HHV-6 management in patients with hematological diseases. http://www.ebmt.org/Contents/Resources/Library/ECIL/Documents/ECIL 4 Update 2011 CMV.pdf. Published 2012, Accessed September 12, 2014.
22. Styczynski J, Einsele H, de la Camara R, Cordonnier C, Engelhard D, Reusser P, Ward K, Ljungman P. Fourth European Conference on Infections in Leukaemia. 2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders. http://www.ebmt.org/Contents/Resources/Library/ECIL/Documents/ECIL4 update 2011 EBV.pdf. Published 2012, Accessed September 12, 2014.
23. Klastersky J, Zinner SH, Calandra T, Klastersky J, Zinner SH, Calandra T, Gaya H, Glauser MP, Meunier F, Rossi M, Schimpff SC, Tattersall M, Viscoli C. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: Lessons from four EORTC trials. Eur J Cancer Clin Oncol 1988; 24 Suppl 1:S35-S45.
24. Viscoli C, Bruzzi P, Glauser M. An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Eur J Cancer 1995; 31A:2013-2022.
25. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Munoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE, European Organization for R, Treatment of Cancer/Invasive Fungal Infections Cooperative G, National Institute of A, Infectious Diseases Mycoses Study Group Consensus G. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-1821.
26. From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel 1990; 161:397-401.
27. Feld R, Paesmans M, Freifeld AG, Klastersky J, Pizzo PA, Rolston KVI, Rubenstein E, Talcott JA, Walsh TJ, Immunocompromised Host S, Multinational Association for Supportive Care in C. Methodology for clinical trials involving patients with cancer who have febrile neutropenia: Updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clin Infect Dis 2002; 35:1463-1468.
28. Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15:S206-S215.
29. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young J-AH, Wingard JR, Infectious Diseases Society of A. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 2011; 52:e56-e93.
30. Neutropenic sepsis: Prevention and management of neutropenic sepsis in cancer patients. National Institute for Health and Care Excellence. http://www.nice.org.uk/Guidance/CG151. Accessed September 12, 2014.
31. Common Terminology Criteria for Adverse Events (CTCAE). In: Institute NC, editor: U.S Department of Health and Human Services; June 14, 2010.
32. Pizzo PA. After empiric therapy: What to do until the granulocyte comes back. Rev Infect Dis 1987: 9:214-219.
33. Magiorakos A, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C, Harbarth S, Hindler J, Kahlmeter G, Olsson-Liljequist B, Paterson D, Rice L, Stelling J, Struelens M, Vatopoulos A, Weber J, Monnet D. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-281.
34. Centre for Disease Control and Prevention (CDC). Central Line-Associated Bloodstream Infection (CLABSI) Event. http://www.cdc.gov/nhsn/PDFs/pscManual/4PSC_CLABScurrent.pdf. Published January 2014, Accessed September 12, 2014.
35. Centre for Disease Control and Prevention. Multidrug-resistant Organism and Clostridium difficile Infection (MDRO/CDI) Module. http://www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO_CDADcurrent.pdf. Published 2012, Accessed September 12, 2014.
36. Miller A, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
37. Ammann RA, Tissing WJE, Phillips B. Rationalizing the approach to children with fever in neutropenia. Curr Opin Infect Dis 2012; 25:258-265.
38. Binz P, Bodmer N, Leibundgut K, Teuffel O, Niggli FK, Ammann RA. Different fever definitions and the rate of fever and neutropenia diagnosed in children with cancer: A retrospective two-center cohort study. Pediatr Blood Cancer 2013:0:799-805.
39. Rodriguez L, Ethier MC, Phillips B, Lehrnbecher T, Doyle J, Sung L. Utility of peripheral blood cultures in patients with cancer and suspected blood stream infections: A systematic review. Support Care Cancer 2012; 20:3261-3267.
40. Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Brit J Haem 2006; 132:3-12.
41. Feld R. Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement? Support Care Cancer 1998; 6:444-448.
42. Haeusler GM, Mechinaud F, Daley A, Starr M, Shann F, Connell TG, Bryant P, Donath S, Curtis N. Antibiotic resistant Gram-negative bacteraemia in paediatric oncology patients - risk factors and outcome Paediatr Infect Dis J 2013.
43. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6:2-8.
44. Rondinelli PIP, Ribeiro KdCB, de Camargo B. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol 2006; 28:665-670.
45. Ammann RA, Bodmer N, Hirt A, Niggli FK, Nadal D, Simon A, Ozsahin H, Kontny U, Kuhne T, Popovic MB, Luthy AR, Aebi C. Predicting adverse events in children with fever and chemotherapy-induced neutropenia: The prospective multicenter SPOG 2003 FN study. J Clin Oncol 2010; 28:2008-2014.
46. Luthi F, Leibundgut K, Niggli FK, Nadal D, Aebi C, Bodmer N, Ammann RA. Serious medical complications in children with cancer and fever in chemotherapy-induced neutropenia: Results of the prospective multicenter SPOG 2003 FN study. Pediatr Blood Cancer 2011; 59:90-95.
47. Hakim H, Flynn PM, Srivastava DK, Knapp KM, Li C, Okuma J, Gaur AH. Risk prediction in pediatric cancer patients with fever and neutropenia. Paediatr Infect Dis J 2010; 29:53-59.
48. Phillips B, Selwood K, Lane S, Skinner R, Gibson F, Chisholm J. Variation in policies for the management of febrile neutropenia in United Kingdom Children's Cancer Study Group centres. Arch Dis Child 2007; 92:495-498.
49. Custer RL, Scarcella JA, Stewart BR. The Modified Delphi Technique - A Rotational Modification. J Voc Tech Educ 1999; 15:1-10.